WALTHAM, Mass.,
The CinCor management team will participate in one-on-one investor meetings during the event. Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.
About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.
About CIN-107
CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the
Contacts: | Investors: |
EVP, CFO and CBDO | ir@CinCor.com |
Source:
2022 GlobeNewswire, Inc., source